← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Avalon GloboCare Corp. (ALBT) 10-Year Financial Performance & Capital Metrics

ALBT • • REIT / Real Estate
Real EstateReal Estate ServicesReal Estate Investment & DevelopmentDiversified Real Estate Investors
AboutAvalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.Show more
  • Revenue $1M +6.2%
  • FFO -$8M +53.6%
  • FFO/Share -8.12 -421.9%
  • FFO Payout 0%
  • FFO per Share -8.12 -421.9%
  • NOI Margin 20.09% +5.9%
  • FFO Margin -570.19% +56.3%
  • ROE -109.23% +39.4%
  • ROA -38.03% +54.1%
  • Debt/Assets 37.36% -10.9%
  • Net Debt/EBITDA -
  • Book Value/Share 7.58 +983.5%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong Piotroski F-Score: 7/9
  • ✓Share count reduced 91.1% through buybacks
  • ✓Trading at only 0.2x book value

✗Weaknesses

  • ✗FFO declining 29.3% TTM
  • ✗Weak momentum: RS Rating 4 (bottom 4%)
  • ✗Low NOI margin of 20.1%
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-2.92%
3Y-1.4%
TTM6.66%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-28.41%

EPS CAGR

10Y-
5Y-
3Y-
TTM-220.13%

ROCE

10Y Avg-95.89%
5Y Avg-104.65%
3Y Avg-77.35%
Latest-47.1%

Peer Comparison

Diversified Real Estate Investors
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TCITranscontinental Realty Investors, Inc.449.59M52.0476.53-4.81%12.04%0.66%0.29%0.21
FRPHFRP Holdings, Inc.466.8M24.4271.820.65%10.9%1%6.21%0.38
NENNew England Realty Associates Limited Partnership184.16M65.2514.638.12%13.54%19.82%
ALBTAvalon GloboCare Corp.4.85M1.14-0.146.19%-13.55%-109.23%1.10
RFLRafael Holdings, Inc.63.21M1.24-1.1943.96%-33.28%-31.03%0.01
LODEComstock Inc.208.13M4.06-1.26136.65%-18.94%-43.25%0.23
STHOStar Holdings116.15M9.12-1.40-12.17%-175.79%-50.29%0.63
BPYPOBrookfield Property Partners L.P.14.91-9.44-3.92%-4.94%-1.17%1.42

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Revenue+0616.45K1.08M1.56M1.55M1.38M1.39M1.2M1.26M1.33M
Revenue Growth %--0.75%0.45%-0.01%-0.11%0.01%-0.14%0.04%0.06%
Property Operating Expenses073.07K829.79K1.17M1.21M987.56K976.45K929.44K1.02M1.07M
Net Operating Income (NOI)+----------
NOI Margin %----------
Operating Expenses+31.01K466.45K2.78M7.96M19.72M12.84M9.25M9.07M15.99M5.2M
G&A Expenses31.01K466.45K2.8M8.02M16.93M11.96M8.22M6.98M7.31M4.35M
EBITDA+144.5K76.96K-3.7M-7.11M-18.87M-12.08M-8.4M-8.33M-15.42M-4.63M
EBITDA Margin %----------
Depreciation & Amortization+175.51K26181.64K522.84K506.74K378.48K438.78K466.28K329.95K300.47K
D&A / Revenue %----------
Operating Income+-31.01K76.93K-3.88M-7.63M-19.38M-12.45M-8.83M-8.79M-15.75M-4.93M
Operating Margin %----------
Interest Expense+00138.11K314.65K608.33K168.76K200.48K3.58M1.35M2.44M
Interest Coverage---28.08x-24.25x-31.85x-73.80x-44.06x-2.46x-11.66x-2.02x
Non-Operating Income71.37K-57533.67K53.53K-1.39M56.66K56.19K-438.38K-398.18K538.69K
Pretax Income+-31.01K77.51K-4.05M-8.05M-18.07M-12.68M-9.09M-11.93M-16.71M-7.9M
Pretax Margin %----------
Income Tax+-175.5K21.93K00000000
Effective Tax Rate %----------
Net Income+-31.01K55.58K-3.46M-7.77M-18.07M-12.68M-9.09M-11.93M-16.71M-7.9M
Net Margin %----------
Net Income Growth %-2.79%-63.33%-1.24%-1.32%0.3%0.28%-0.31%-0.4%0.53%
Funds From Operations (FFO)+----------
FFO Margin %----------
FFO Growth %--0.62%-60.03%-1.21%-1.42%0.3%0.3%-0.33%-0.43%0.54%
FFO per Share+----------
FFO Payout Ratio %----------
EPS (Diluted)+-0.180.01-0.53-1.08-2.41-1.61-1.09-1.36-1.59-8.44
EPS Growth %-1.06%-49.62%-1.04%-1.23%0.33%0.32%-0.25%-0.17%-4.31%
EPS (Basic)-0.180.01-0.53-1.08-2.41-1.61-1.09-1.36-1.59-8.44
Diluted Shares Outstanding175K5.11M6.5M7.2M7.51M7.95M8.49M9.33M10.53M936.61K

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Assets+1943.71M12.67M13.4M10.49M10.37M10.24M19.75M20.58M20.99M
Asset Growth %-19104.71%2.42%0.06%-0.22%-0.01%-0.01%0.93%0.04%0.02%
Real Estate & Other Assets+0025.32K7.88M7.83M7.94M374.76K16.74M7.47M7.09M
PP&E (Net)029548.03K249.56K601.42K616.45K506.85K149.18K166.33K17.62K
Investment Securities001000K385.16K483.1K521.76K1000K485.01K1000K1000K
Total Current Assets+1943.71M3.23M3.63M1.57M1.29M1.15M2.37M850.87K3.24M
Cash & Equivalents1942.89M3.03M2.25M764.89K726.58K807.54K1.99M285.4K2.86M
Receivables070.23K48.65K52.22K243.89K35.4K90.87K134.63K234.66K122.96K
Other Current Assets049.8K42.46K127.26K562.32K31.11K18.31K247.99K270.55K103.94K
Intangible Assets001.58M1.26M000000
Total Liabilities5.6K160.32K5.36M2.14M6.03M6.25M7.16M8.59M13.21M13.88M
Total Debt+4.7K01.5M1M3.19M3.73M3.3M4.57M8.64M7.84M
Net Debt4.51K-2.89M-1.53M-1.25M2.43M3.01M2.49M2.58M8.35M4.98M
Long-Term Debt0001M3.19M3.59M2.75M4.56M6.45M0
Short-Term Borrowings4.7K01000K000541.4K01000K1000K
Capital Lease Obligations00000143.33K5.9K11.44K134.25K10.71K
Total Current Liabilities+5.6K160.32K5.36M1.14M2.84M2.59M4.4M3.58M6.76M13.88M
Accounts Payable90070.23K296.7K84.32K87.19K0000
Deferred Revenue-122.96K012.77K28.96K023.51K8.64K27.68K11.43K38.35K
Other Liabilities0000000450K00
Total Equity+-5.41K3.55M7.31M11.25M4.47M4.12M3.08M11.16M7.37M7.1M
Equity Growth %-656.97%1.06%0.54%-0.6%-0.08%-0.25%2.62%-0.34%-0.04%
Shareholders Equity-5.41K3.55M7.89M12.12M4.47M4.12M3.08M11.16M7.37M7.1M
Minority Interest00-585.39K-862.2K000000
Common Stock7006.16K7.03K7.38K7.67K8.28K8.9K1K1.1K145
Additional Paid-in Capital28.4K3.68M11.49M24.15M34.59M46.86M54.89M65.95M67.89M72.02M
Retained Earnings-34.51K-53.37K-3.52M-11.29M-29.36M-42.04M-51.13M-63.06M-79.77M-87.67M
Preferred Stock00000009M20M23.5M
Return on Assets (ROA)-159.82%0.03%-0.42%-0.6%-1.51%-1.22%-0.88%-0.8%-0.83%-0.38%
Return on Equity (ROE)-0.03%-0.64%-0.84%-2.3%-2.95%-2.52%-1.68%-1.8%-1.09%
Debt / Assets24.23%-0.12%0.07%0.3%0.36%0.32%0.23%0.42%0.37%
Debt / Equity--0.21x0.09x0.71x0.91x1.07x0.41x1.17x1.10x
Net Debt / EBITDA0.03x-37.50x--------
Book Value per Share-0.030.691.121.560.590.520.361.200.707.58

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-30.11K13.98K-1.34M-4.4M-7.08M-7.55M-5.02M-7.04M-6.5M-4.97M
Operating CF Growth %-1.46%-96.8%-2.28%-0.61%-0.07%0.33%-0.4%0.08%0.24%
Operating CF / Revenue %----------
Net Income-31.01K55.58K-4.05M-8.05M-18.07M-12.68M-9.09M-11.93M-16.71M-7.9M
Depreciation & Amortization026181.64K522.84K506.74K378.48K438.78K466.28K329.95K300.47K
Stock-Based Compensation052.55K993K3.09M9.21M5.49M2.11M1.11M1.18M521.51K
Other Non-Cash Items59.67K52.55K1.32M52.97K1.39M7.55K17.31K3.11M8.73M3.34M
Working Capital Changes900-94.17K213.98K-12.51K1.64M-856.21K1.5M206.89K-35.07K-1.23M
Cash from Investing+0-930.33K-8.01M-1.31M-552.97K-169.19K-68.14K-9.05M-22.16K-100K
Acquisitions (Net)0-230K72.03K-803.16K-159.19K-57.97K-40.3K-52K0-100K
Purchase of Investments00-7.01M-844.66K-175.51K-169.19K0-9.05M00
Sale of Investments0000175.51K001000K00
Other Investing0-700K-7.16M-391.51K-16.32K57.97K-10.33K-9M00
Cash from Financing+30.3K3.79M9.5M5.04M6.15M7.66M5.17M17.26M4.83M7.64M
Dividends Paid0000000000
Common Dividends0000000000
Debt Issuance (Net)1.8K01000K-500K1000K400K1000K1000K1000K-420.47K
Share Repurchases000-522.5K000000
Other Financing-11.5K150K2.85M-1.49M00-240.43K-290.52K74.95K1.7M
Net Change in Cash+1942.78M140.84K-774.75K-1.49M-38.31K80.96K1.18M-1.71M2.57M
Exchange Rate Effect0-92.05K-7.24K-113.13K-9.47K12.69K3.44K10.08K-3.97K1.45K
Cash at Beginning0109.59K2.89M3.03M2.25M764.89K726.58K807.54K1.99M285.4K
Cash at End1942.89M3.03M2.25M764.89K726.58K807.54K1.99M285.4K2.86M
Free Cash Flow+-30.11K13.65K-2.27M-4.51M-7.46M-7.55M-5.04M-7.04M-6.53M-4.97M
FCF Growth %-1.45%-167.27%-0.99%-0.65%-0.01%0.33%-0.4%0.07%0.24%
FCF / Revenue %----------

Key Ratios

Metric2015201620172018201920202021202220232024
FFO per Share0.830.01-0.5-1.01-2.34-1.55-1.02-1.23-1.56-8.12
FFO Payout Ratio0%0%0%0%0%0%0%0%0%0%
NOI Margin-88.15%22.99%24.84%21.98%28.32%29.8%22.69%18.97%20.09%
Net Debt / EBITDA0.03x-37.50x--------
Debt / Assets2422.68%-11.84%7.47%30.41%36.01%32.2%23.16%41.95%37.36%
Interest Coverage---28.08x-24.25x-31.85x-73.80x-44.06x-2.46x-11.66x-2.02x
Book Value / Share-0.030.691.121.560.590.520.361.20.77.58
Revenue Growth--74.8%44.98%-1.02%-10.9%0.96%-13.57%4.45%6.19%

Revenue by Segment

2023
Corporate Other Member432.62K
Corporate Other Member Growth-

Frequently Asked Questions

Growth & Financials

Avalon GloboCare Corp. (ALBT) reported $1.4M in revenue for fiscal year 2024.

Avalon GloboCare Corp. (ALBT) grew revenue by 6.2% over the past year. This is steady growth.

Avalon GloboCare Corp. (ALBT) reported a net loss of $18.9M for fiscal year 2024.

Dividend & Returns

Avalon GloboCare Corp. (ALBT) has a return on equity (ROE) of -109.2%. Negative ROE indicates the company is unprofitable.

Industry Metrics

Avalon GloboCare Corp. (ALBT) generated Funds From Operations (FFO) of $-18.7M in the trailing twelve months. FFO is the primary profitability metric for REITs.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.